SRSD107 for People With Chronic Coronary or Peripheral Artery Disease
Tests SRSD107 against a placebo in adults with coronary or peripheral artery disease.
Plain-language title generated from the registry record
Registry title: A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with a history of chronic coronary and/or peripheral arterial disease, to study the drug SRSD107 with aspirin as background therapy.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- History of chronic coronary and/or peripheral arterial disease.
- Earlier treatment
- People who got an investigational drug within 30 days or 5 half-lives (whichever is longer) before dosing, or who used SRSD107 before, cannot join.
Main reasons for not taking part
- Known bleeding disorder
- Severe heart failure (ejection fraction below 35%, or NYHA class III or IV symptoms)
- Genetic or other non-ischemic cardiomyopathies not related to atherosclerotic cardiovascular disease
- Alcohol abuse or addictive drug use within 6 months of screening (cannabis products allowed)
- Previous use of SRSD107
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07318155, who can take part
Where in China
- Fuwai HospitalBeijing, ChinaContact: MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sirius Therapeutics Co., Ltd.
- Trial code
- NCT07318155
- Record updated
- 29 April 2026
- Original description
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.Read full original descriptionShow less
A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.
Inclusion: Able to comprehend and willing to sign an ICF and to abide by the study restrictions; Males or females aged 18 to 75 years, inclusive; Body mass index (BMI) between 18.0 and 35.0 kg/m2, inclusive; History of chronic coronary and/or peripheral arterial disease.
Exclusion: Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study; Previous use of SRSD107; Known bleeding disorder; Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease; History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening; Severe heart failure with known left ventricular ejection fraction <35%, or New York Heart Association (NYHA) class III or IV symptoms.